|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients显示文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal. | Markus Moehler Martin F Sprinzl Murad Abdelfattah Carl C Schimanski Bernd Adami Werner Godderz Klaus Majer Dimitri Flieger Andreas Teufel Juergen Siebler Thomas Hoehler Peter R Galle Stephan Kanzler | 2009 | World Journal of Gastroenterology2009，15，4： | 10 |
| 2 | Engrafted bone marrow-derived flk-(1+) mesenchymal stem cells regenerate skin tissue显示文摘 | Deng W Han Q Liao L Li C Ge W Zhao Z You S Deng H Murad F Zhao RC | 2006 | 中国生物学文摘2006，20，5： | 2 |
| 3 | Pt based nanocompo sites (mono/bi/tri-metallic) decorated using different carbon supports for methanol electro-oxidation in acidic and basic media 显示文摘 | Singh B Murad L Laffir F | 2011 | Nanoscale2011，3，8： | 1 |
| 4 | Vasodilatory effects of cinnamaldehyde and its mechanism of action in the rat aor- ta显示文摘 | Xue YL Shi HX Murad F | 2011 | Vasc Health Risk Manag2011，7，： | 1 |
| 5 | Nitric oxide (NO)-biogeneration, regulation, and relevance to human dieseases 显示文摘 | Bian K Murad F | 2003 | Front Biosci2003，8，： | 1 |
| 6 | Activation of guanylate cyclase by superoxide dis-mutase and hydroxyl radical:a physiological regulator of guanosine 3' ,5'-monophosphate formation显示文摘 | Mittal CK Murad F | 1977 | Proc Natl Acad Sci U S A1977，74，43： | 1 |
| 7 | Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP显示文摘 | Rapoport RM Murad F | 1983 | Circ Res1983，52，3： | 1 |
| 8 | Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP显示文摘 | Papoport RM Murad F | | 0，，03： | 1 |
| 9 | Estradiol rapidly inhibits soluble guanylyl cyclase expression in rat uterus 显示文摘 | Krumenacker JS Hyder SM Murad F | 2001 | Proc NailAcad Sei USA2001，98，2： | 1 |
| 10 | Diabetes-associated nitration of tyrosine and inactivation of succinyl CoA: 3-oxoacid CoA-transferase显示文摘 | Turko IV Marcondes S Murad F | 2001 | Am J Physiot Heart Circ Physiol2001，281，6： | 1 |
| 11 | Signal transduction using nitric oxide and cyclic guanosine monophosphate 显示文摘 | Murad F | 1996 | JAMA1996，276，14： | 1 |
| 12 | Agonist-inducedendoth elium-dependent laxation in rat thoracic aorta may be mediated through cGMP显示文摘 | Rapport RM Murad F | 1983 | Cire Res1983，52，： | 1 |
| 13 | Discovery of some of the biological effects of nitric oxide and its role in cell signaling 显示文摘 | Murad F | 1999 | Angew Chem Int Ed1999，38，： | 1 |
| 14 | Nitric oxide and cGMP signaling显示文摘 | Mc Donald L J Murad F | 1995 | Adv Pharmacol1995，34，： | 1 |
| 15 | Vascular system: role of nitric oxide in cardiovascular diseases 显示文摘 | Bian K Doursout M F Murad F | 2008 | J Clin Hypertens2008，10，4： | 1 |
| 16 | Nitric oxide (NO) -biogeneration, regulation,and relevance to human diseases显示文摘 | BIAN K MURAD F | 2003 | Front Biosci2003，8，3： | 1 |
| 17 | Discovery of some of the biological effects of nitric oxide and its role in cell signaling显示文摘 | Murad F | 1999 | Biosci Rep1999，19，3： | 1 |
| 18 | YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components 显示文摘 | Martin E Lee YC Murad F | 2001 | Proc Nail Acad Sci USA2001，98，12： | 1 |
| 19 | Nitric oxide accelerates the recovery from burn wounds显示文摘 | Zhu H Bian K Murad F | 2007 | World J Surg2007，31，4： | 1 |
| 20 | Nitric oxide signaling: would you believe that a simpl free radical could be a second messenger, autacoid, paracrine sub stance, neurotransmitter, and hormone? 显示文摘 | MURAD F | 1998 | Recent Prog Horm Re1998，53，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员